Arcturus Therapeutics
ARCT
145 hedge funds and large institutions have $283M invested in Arcturus Therapeutics in 2025 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 50 reducing their positions, and 24 closing their positions.
181% more call options, than puts
Call options by funds: $3.53M | Put options by funds: $1.26M
0.25% less ownership
Funds ownership: 98.39% → 98.14% (-0.25%)
4% less capital inflows, than outflows
Capital inflows: $35.2M | Capital outflows: $36.8M
8% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 50
2% less funds holding
Funds holding: 148 → 145 (-3)
13% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.33M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$6.18M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$4.17M |
| 4 |
Vestal Point Capital
New York
|
+$3.36M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MPM BioImpact
Boston,
Massachusetts
|
-$7.81M |
| 2 |
BlackRock
New York
|
-$3.64M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.97M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$2.57M |
| 5 |
J. Goldman & Co
New York
|
-$2.55M |
ARCT Hedge Fund Activity: Q1 2025 in Review
145 of the 7,487 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2025, worth a combined $283M — down 37% from $453M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ARCT and 21 opened new positions — a net loss of 3 holders — while 50 trimmed existing stakes and 46 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $7.33M. The largest seller was MPM BioImpact, exiting entirely with an estimated $7.81M sold.
- 145 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2025, down from 148 in Q4 2024.
- Funds reported $283M of Arcturus Therapeutics stock for Q1 2025, down 37% quarter-over-quarter.
- 21 funds opened new Arcturus Therapeutics positions in Q1 2025 and 24 closed out, a net change of -3 holders.
- The largest Arcturus Therapeutics buyer in Q1 2025 was Millennium Management, an estimated $7.33M added.
- The largest Arcturus Therapeutics seller in Q1 2025 was MPM BioImpact, an estimated $7.81M sold.
Based on aggregated 13F filings for Q1 2025.